SCHEMBL29922980

SCHEMBL29922980

Cc1ncc(-c2ccccc2)c(O)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 4/20 0.46
NTRK3 Q16288 2/20 0.45
AKT1 P31749 1/20 0.44
AKT2 P31751 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.42
MAPT P10636 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ALOX5 P09917 1/20 0.42
BACE1 P56817 1/20 0.40
ESR2 Q92731 1/20 0.40
HPGD P15428 2/20 0.40
GFER P55789 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21585741 0.80 L3MBTL1 (0.45) NTRK1NTRK3AKT1AKT2L3MBTL1
SCHEMBL13081603 0.78 L3MBTL1 (0.47) NTRK1NTRK3AKT1AKT2L3MBTL1
SCHEMBL10205892 0.78 NTRK1 (0.58) NTRK1NTRK3ADORA2AADORA1L3MBTL1
SCHEMBL27855202 0.77 L3MBTL1 (0.42) NTRK1NTRK3AKT1AKT2ADORA2A
SCHEMBL5420324 0.77 NTRK1 (0.49) NTRK1AKT1AKT2ADORA2AADORA1
SCHEMBL6866112 0.77 NTRK1 (0.49) NTRK1NTRK3L3MBTL1MAPTNPSR1
SCHEMBL19412636 0.75 CLK1 (0.37) ALOX5ESR2KMT2ACYP2C9
SCHEMBL25490523 0.74 L3MBTL1 (0.41) NTRK1NTRK3AKT1AKT2ADORA2A
SCHEMBL10555132 0.73 ADORA2A (0.44) AKT1AKT2ADORA2AADORA1L3MBTL1
SCHEMBL18371486 0.73 BRS3 (0.40) AKT2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612371-B2 Sigma-1 receptor ligands and therapeutic uses thereof UNIVERSITE DE STRASBOURG (FR) 2026-04-28 US disclosed
EP-4076456-B1 SIGMA-1 RECEPTOR LIGANDS AND THERAPEUTIC USES THEREOF UNIV STRASBOURG (FR) 2024-05-01 EP disclosed
US-20230076057-A1 SIGMA-1 RECEPTOR LIGANDS AND THERAPEUTIC USES THEREOF INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2023-03-09 US disclosed
EP-4076456-A1 SIGMA-1 RECEPTOR LIGANDS AND THERAPEUTIC USES THEREOF Université de Strasbourg (FR) 2022-10-26 EP disclosed
CN-114980891-A Sigma-1 receptor ligands and therapeutic uses thereof 斯特拉斯堡大学 2022-08-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612371-B2 Sigma-1 receptor ligands and therapeutic uses thereof SIGMAR1, OPRL1, OPRM1 NTRK1 133/4885NTRK3 289/4885AKT1 1513/4885
US-20230076057-A1 SIGMA-1 RECEPTOR LIGANDS AND THERAPEUTIC USES THEREOF SIGMAR1, OPRL1, TMEM97 NTRK1 261/4885NTRK3 400/4885AKT1 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.